https://imd354inhibitor.com/tw....o-scabies-acne-outbr
Additional endpoints included recurrent VTE and major bleeding as specific endpoints. Cohort risk ended up being compared using Cox regression and reported as risk ratios (HRs) with 95% self-confidence periods (CIs). Results We identified 2097 rivaroxaban and 2842 warfarin users with incident VTE. At 6-months, no significant differences in the composite endpoint (HR = 0.96, 95%Cwe = 0.75-1.24), recurrent VTE (HR = 1.02, 95%Cwe = 0.76-1.36) or significant bleeding alone (HR = 0.93, 95%
Like
Comment
Share
